New hope for kids with liver fluke: drug trial launches

NCT ID NCT07262814

Not yet recruiting Disease control Sponsor: Jennifer Keiser Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 15, 2026 · Updated 3 times

Summary

This study tests different doses of a drug called arpraziquantel in children aged 6-7 who are infected with a liver fluke parasite (Opisthorchis viverrini). The goal is to find the safest and most effective dose to cure the infection. 125 children will receive one of several doses, and researchers will check if the parasite is gone after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: arpraziquantel (a drug to treat parasitic worm infections)
What this could lead to: If successful, this could provide a safe and effective treatment for liver fluke infection in young children, helping to reduce disease burden in affected communities.
What could go wrong: This is a small, early-phase trial (Phase 2) with only 125 children. The optimal dose may not be found, or the drug may not work as well as hoped. Side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates